Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Potential Effect of Innovative Cell-based Therapy Using Adipose-derived Stromal Vascular Fraction in Patients With Autoimmune Xerostomia (XEROCELL)

NCT05857358 is registered in ClinicalTrials.gov with Assistance Publique Hopitaux De Marseille as lead sponsor.

NCT NCT05857358
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05857358 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Potential Effect of Innovative Cell-based Therapy Using Adipose-derived Stromal Vascular Fraction in Patients With Autoimmune Xerostomia (XEROCELL)
Lead sponsor
Assistance Publique Hopitaux De Marseille
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
January 31, 2024
Completion date
August 31, 2027
Enrollment
18 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

xerostomia